Traders Alert: Anacor Pharmaceuticals Inc(NASDAQ:ANAC), Micron Technology, Inc. (NASDAQ:MU), Affymax, Inc.(NASDAQ:AFFY)

Lakeway, NY -- (SBWIRE) -- 03/22/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Anacor Pharmaceuticals Inc(NASDAQ:ANAC) shares soared 38.53% to $6.70. The company, on March 21, announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 - 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance.

Is ANAC a Strong Buy After The Recent Gain? Let’s Find out Here

Micron Technology, Inc. (NASDAQ:MU) shares increased 9.59% to $9.93. The company, on Mar. 21, reported a second-quarter loss of $286 million, or 28 cents a share, compared with a loss of $282 million, or 29 cents a share, for the year-earlier period. Revenue increased to $2.08 billion from $2.01 billion in the same quarter last year. Analysts were expecting the chip company to report a loss of 20 cents a share, on revenue of $1.92 billion.

Additionally, MU‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued on Mar. 18. They currently have a $11.00 price target on the stock, up from their previous price target of $10.00.

Is MU a Strong Buy After The Recent Gain? Let’s Find out Here

Affymax, Inc.(NASDAQ:AFFY) shares climbed 6.66% to $1.58. The company, on Mar. 18, announced that it will reduce its workforce as part of a plan to focus the company's resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving OMONTYS® (peginesatide) Injection following the nationwide voluntary recall of product from the market. This action will reduce the company's workforce by approximately 230 employees (or 75%), which includes its commercial and medical affairs field organizations as well as other officers and employees.

Is AFFY Signaling a Buy Signal After The recent Volatility? Let’s Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.